Global ulcerative colitis drug market set to see 'reasonable' growth to 2015
According to Ulcerative Colitis - Drug Pipeline Analysis and Market Forecasts to 2015, a news report added to the offering of Research and Markets, this therapeutic sector is expected experience 'reasonable' growth over the review period.
The report estimates the global ulcerative colitis market was valued at $1.3 billion in 2008. It is projected to grow by a steady 5.1% annually for the next seven years to reach $1.9 billion by 2015. The growth will be driven by several factors, such as intensification in UC prevalence and expected approvals of biologics in the future. Barriers for the UC market include diagnostic limitations and a complex disease etiology, which moderately affect the growth of the market, the report says. These barriers can be overcome with technological advances in the field of drug discovery and disease diagnosis.
Remains remarkably competitive
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze